Point72 Asset Management increased stake in Tricida, Inc. By Investing.com

Point72 Asset Management increased stake in Tricida, Inc. By Investing.com


© Reuters. Point72 Asset Management increased stake in Tricida, Inc.

On the 23rd of March, Point72 Asset Management bought 1.3 million Tricida , Inc. (NASDAQ:) shares for $6.6 million at an average price of $5.01 per share.
Shares of Tricida, Inc. are down -5.39% since the transaction.

Point72 Asset Management’s holding in Tricida, Inc. increased to about 2.5 million shares with the purchase.

Point72 Asset Management first bought Tricida, Inc. stock in the fourth quarter of 2018.
Point72 Asset Management also owns AstraZeneca PLC ADR (NASDAQ:), Merck (MRK), Eli Lilly & Co (NYSE:) and Chinook Therapeutics, Inc. (KDNY).
Tricida, Inc. is its number thirty nine position by number of shares and market value among biotechnology & life sciences stocks.

Other investors who also added to their Tricida, Inc. shares include Citigroup (NYSE:) and Millennium Management.
In contrast, the T. Rowe Price Equity Income Fund and Squarepoint Ops reduced TCDA shares.

Point72 Asset Management has also recently reduced their share in VYNE Therapeutics INC (VYNE) and MacroGenics, Inc. (NASDAQ:).
The total value of the shares sold is estimated at around $53 million.

In addition, Point72 Asset Management established new holdings in CytomX Therapeutics, Inc. (NASDAQ:) and AnaptysBio, Inc. (NASDAQ:).
Point72 Asset Management also added to their share in Affimed N.V. (NASDAQ:), Kadmon Holdings Inc (NASDAQ:), Bicycle Therapeutics plc (NASDAQ:) and Mereo BioPharma Group plc (MREO).
The total value of the shares bought is estimated at around $123 million.

Point72 Asset Management also reduced their share in Syros Pharmaceuticals, Inc. (NASDAQ:), American Eagle Outfitters Inc (NYSE:), Childrens Place Inc (PLCE), Cytokinetics Inc (NASDAQ:), ANGI Homeservices Inc (NASDAQ:), Dave & Busters Entertainment Inc (NASDAQ:), Otonomy, Inc. (NASDAQ:), Calithera Biosciences, Inc. (CALA), Chiasma Inc (NASDAQ:) and Fulcrum Therapeutics, Inc. (NASDAQ:).
The total value of the shares sold is estimated at around $58 million.

In addition, Point72 Asset Management established new holdings in Curis Inc (CRIS), Miragen Therapeutics Inc (NASDAQ:), Aeglea BioTherapeutics, Inc. (AGLE), Hims & Hers Health, Inc. (HIMS) and Paya Holdings Inc. (PAYA).
Point72 Asset Management also added to their share in Alliance Data Systems Corp (NYSE:), BioCryst (NASDAQ:) Pharmaceuticals Inc (BCRX), BGC Partners Inc (NASDAQ:), Revolve Group Inc (NYSE:) and Acorda Therapeutics Inc (NASDAQ:).
The total value of the shares bought is estimated at around $270 million.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





Source link

Leave a comment

Send a Comment

Your email address will not be published. Required fields are marked *